Found: 8
Select item for more details and to access through your institution.
Certolizumab pegol treatment in axial spondyloarthritis mitigates fat lesion development: 4-year post-hoc MRI results from a phase 3 study.
- Published in:
- Rheumatology, 2022, v. 61, n. 7, p. 2875, doi. 10.1093/rheumatology/keab841
- By:
- Publication type:
- Article
Achievement of higher thresholds of clinical responses and lower levels of disease activity is associated with improvements in workplace and household productivity in patients with axial spondyloarthritis.
- Published in:
- Therapeutic Advances in Musculoskeletal Disease, 2023, p. 1, doi. 10.1177/1759720X231189079
- By:
- Publication type:
- Article
Achievement of higher thresholds of clinical responses and lower levels of disease activity is associated with improvements in workplace and household productivity in patients with axial spondyloarthritis.
- Published in:
- Therapeutic Advances in Musculoskeletal Disease, 2023, v. 15, p. 1, doi. 10.1177/1759720X231189079
- By:
- Publication type:
- Article
Minimal Impact of the COVID‐19 Pandemic on Disease Activity and Health‐Related Quality of Life in Patients With Ankylosing Spondylitis Receiving Bimekizumab: Exploratory Analyses From a Phase 2b Open‐Label Extension Study.
- Published in:
- ACR Open Rheumatology, 2022, v. 4, n. 9, p. 819, doi. 10.1002/acr2.11486
- By:
- Publication type:
- Article
Certolizumab Pegol Efficacy in Patients With Non‐Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C‐Reactive Protein Status: An Analysis From the C‐axSpAnd Study.
- Published in:
- ACR Open Rheumatology, 2022, v. 4, n. 9, p. 794, doi. 10.1002/acr2.11469
- By:
- Publication type:
- Article
Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: Three‐Year Results From a Phase IIb Randomized Controlled Trial and Its Open‐Label Extension Study.
- Published in:
- Arthritis & Rheumatology, 2022, v. 74, n. 12, p. 1943, doi. 10.1002/art.42282
- By:
- Publication type:
- Article
Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE.
- Published in:
- Rheumatology & Therapy, 2020, v. 7, n. 3, p. 581, doi. 10.1007/s40744-020-00214-7
- By:
- Publication type:
- Article
Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review.
- Published in:
- Therapeutic Advances in Musculoskeletal Disease, 2020, v. 12, p. 1, doi. 10.1177/1759720X20906040
- By:
- Publication type:
- Article